Blood Biomarkers to Study Alzheimers and Brain Injury Effects on Thinking, Daily Function, and Survival in Hospitalized Older Adults A Multicenter, Prospective Observational Study with Three Patient Groups

What this Trial Is About

Researchers are evaluating blood biomarkers related to Alzheimers Disease and neuro-injury to understand their association with cognitive and functional decline, mortality, and hospital readmission in older hospitalized patients. This multicenter, prospective observational study aims to validate a prognostic algorithm developed from a prior retrospective analysis of biomarkers in a cohort of 700 geriatric patients. The study integrates clinical, laboratory, and biomarker data to assess these relationships in a real-world population. The study involves three groups of hospitalized patients those with acute neurological disorders such as stroke or delirium, those with major neurocognitive disorder dementia, and those hospitalized for non-neurological diseases without dementia. Blood samples will be collected at baseline to measure amyloid -42, tau proteins, neuro-injury markers, neuroinflammation markers, and astrocyte activation. The research will observe participants over 12 months to record mortality and hospital readmission rates. Participants will undergo comprehensive geriatric assessments and evaluations of cognitive function and frailty at the start of the study. Blood biomarker levels will be analyzed alongside clinical data to explore their association with outcomes. The primary outcomes include all-cause mortality and number of hospital readmissions within 12 months of enrollment. This observational study does not involve treatment interventions but focuses on monitoring and data collection to improve understanding of disease progression and risks in elderly hospitalized patients.

Blood Biomarkers for Alzheimer Disease and Neuro-injury to Estimate the Association With Cognitive/Functional Decline and Mortality in a Real-world Population of GERiatric Hospitalized Patients (BAD-GER)